Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective

BACKGROUND: The availability of the tyrosine-kinase inhibitor (TKI), imatinib, and later introduction of second generation TKIs, dasatinib and nilotinib, have not only improved clinical outcomes of patients with chronic myeloid leukemia (CML), but also provide multiple therapeutic options for CML pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirji, Ishan, Gupta, Shaloo, Goren, Amir, Chirovsky, Diana R, Moadel, Alyson B, Olavarria, Eduardo, Victor, Timothy W, Davis, Catherine C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851879/
https://www.ncbi.nlm.nih.gov/pubmed/24099272
http://dx.doi.org/10.1186/1477-7525-11-167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851879/
https://www.ncbi.nlm.nih.gov/pubmed/24099272
http://dx.doi.org/10.1186/1477-7525-11-167

Ejemplares similares